Sutura

Sutura Therapeutics is a biotechnology company focused on developing next-generation gene-modifying medicines for rare and orphan diseases. The company's core technology is the Peptomer platform, a proprietary delivery system that utilizes specific peptides to transport antisense oligonucleotides directly into target cells. This platform is designed to overcome the delivery challenges that have historically limited the effectiveness of RNA-based therapeutics, particularly in muscle and brain tissue. Their lead development program, SUT-001, is currently in pre-clinical development for the treatment of Duchenne Muscular Dystrophy. Beyond neuromuscular disorders, the company is exploring applications of its technology in metabolic diseases and oncology. Sutura was founded as a spin-out from academic research and is headquartered in Oxford, UK.